Top 50 Cell Line Development in Europe

Cytena develops single-cell printing technology and automated solutions for cell line development, enabling the efficient production of stable cell lines for therapeutic applications. Their systems streamline workflows for biopharmaceutical companies, reducing the time and cost associated with developing biologics while ensuring compliance with regulatory standards.

Roslin Technologies develops pluripotent animal stem cells for the cultivated meat industry, providing scalable cell lines that can differentiate into muscle and fat tissues. This technology addresses the growing global demand for sustainable protein by enabling the production of real meat without raising animals, thereby reducing environmental impact and improving animal welfare.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

Alvotech specializes in the development and manufacturing of biosimilars through a vertically integrated process that includes cell line development and fill-finish manufacturing. This approach enhances access to affordable biologic medicines, addressing the high costs associated with traditional biologic therapies.

Quest develops proprietary cell lines and patented food ingredients to enable scalable and cost-effective production for the cultivated meat and alternative protein industries. Their solutions address key bottlenecks in product quality and manufacturing, facilitating the widespread adoption of sustainable protein sources.

The startup develops a DNA integration platform that enhances the engineering of cell lines for gene and cell therapies, specifically targeting the production of recombinant adeno-associated virus vectors. By improving viral vector yield and efficacy, the company enables biopharmaceutical firms to produce more effective therapies for serious diseases.

The startup provides contract development services for preclinical and clinical drug projects, specializing in the supply of ready-to-inject adipose-derived allogeneic stem cells. This offering enables healthcare companies to lower manufacturing costs and improve the affordability of cell therapies.

Mytos is developing a fully automated platform for the manufacture of any human cell type, utilizing advanced robotics and software to streamline cell culture processes. This technology addresses the challenges of contamination and human error in cell production, enabling consistent, high-quality output at a scale that allows one technician to achieve the productivity of ten scientists working manually.

Scarlet Therapeutics develops a proprietary platform that generates therapeutic red blood cells (tRBCs) containing high levels of therapeutic proteins, enabling targeted treatment for diseases such as hyperammonemia, hyperoxaluria, cancer, and autoimmune disorders. By utilizing cell lines for production instead of donated stem cells, the company addresses manufacturing challenges and enhances the efficacy of red blood cell-based therapies.

The startup has developed a gene silencing platform that enables the engineering of programmable and adaptive cell therapies, allowing for the creation of iPSC-derived products that respond to specific intra- and extra-cellular signals. This technology enhances the efficacy, safety, and accessibility of cell therapies, addressing the limitations of current therapeutic approaches.

Extracellular is a contract development and manufacturing organization (CDMO) that specializes in biomanufacturing processes for cultivated meat and seafood, utilizing non-human cell culture technologies to produce biomass efficiently. The company addresses the challenge of scaling production in sustainable biotechnology by providing tailored cell culture media and large-scale bioreactor capabilities to accelerate time to market for its clients.

Cellino is developing a scalable, automated biomanufacturing system that produces personalized cell therapies using patient-derived cells. This technology addresses the challenges of high costs and lengthy production times in delivering potentially curative treatments for individual patients.

Astraveus is developing the Lakhesys - The Benchtop Cell Factory™, a microfluidics-powered platform that integrates hardware, software, and consumables for cell and gene therapy manufacturing. This solution enhances development throughput by up to 100 times while reducing resource consumption by 10 to 20 times, making cell therapies more accessible to patients.

SIMABS NV has developed a continuous bioprocessing platform for the rapid and cost-effective development and GMP manufacturing of monoclonal and bispecific antibodies, addressing the need for high-quality biologics in personalized medicine. Their integrated approach offers a complete solution, including cell line development and regulatory support, enabling biopharmaceutical companies to accelerate their product development timelines while reducing costs.

CustomCells specializes in the design and manufacturing of high-performance battery technology tailored for electric mobility applications. The company addresses the limitations of current energy storage solutions by providing scalable, customer-centric batteries that enhance the efficiency and sustainability of automotive and aviation industries.

PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.

TreeFrog Therapeutics develops proprietary C-Stem™ technology to produce scalable, high-quality cell therapies, including a lead program targeting Parkinson’s disease. The company addresses the need for effective and safe regenerative medicine by enabling the production of billions of cells in a single batch, facilitating clinical trials and patient access.

This company accelerates biomanufacturing breakthroughs by designing cell-specific culture media using an AI-driven platform. Their MediOP™ technology integrates AI, robotics, and cell biology to create custom media solutions for advanced therapies, biologics, and cellular agriculture. Multus offers services for tailored media design, catalog formulations, and scalable supply chains globally.

Cellcolabs specializes in the industrial-scale, GMP production of high-quality mesenchymal stromal cells (MSCs) for research and clinical applications. By providing these cells, the company aims to enhance the availability and affordability of MSCs, facilitating advancements in treatments for severe and incurable diseases.

Thymmune Therapeutics is developing a machine learning platform for thymic cell engineering to enhance the generation and function of thymic-derived T-cells. This technology aims to improve the efficacy and precision of T-cell therapies for cancer and autoimmune diseases by optimizing immune cell treatments.

Unicorn Biotechnologies develops bio-reactors that standardize, digitize, and automate cell culture workflows, enabling efficient scaling from pilot to commercial manufacturing. Their technology addresses the challenges of batch failures and high costs in cell-based production, allowing researchers to focus on experimental design and analysis.

The startup develops machine-learning tools to design cell factories capable of producing a wide range of products, including food, fabrics, and medicines. By simplifying the complex process of cellular manufacturing, the company aims to replace traditional farms and factories, promoting a more sustainable production model.

Mogrify develops in vivo reprogramming therapies that utilize a proprietary platform to identify key transcriptomic and epigenetic factors necessary for direct cellular conversion. This technology aims to restore lost cell types in patients with degenerative diseases, particularly in otology, ophthalmology, and diabetes, addressing significant unmet clinical needs.

Antiverse utilizes machine learning and advanced cell line engineering to design target-specific antibody libraries for challenging drug targets, including G-protein coupled receptors and ion channels. The platform accelerates the antibody discovery process, enabling the development of functional therapeutics within six months, addressing the lengthy timelines typically associated with traditional drug development methods.

The startup operates a cell therapy research and manufacturing platform that enhances process control and scalability in autologous cell and gene therapy bioprocessing. By enabling parallel execution of cell culture conditions, the platform reduces manufacturing costs while improving efficiency in process development.

Limula provides a modular, automated platform that integrates a bioreactor and centrifuge for the on-demand, at-scale manufacturing of cell therapies. This technology addresses the high costs and complexity of producing personalized cell therapies, enabling efficient processing of various cell types in a single device.

Ori Biotech has developed the IRO® platform, a fully automated and standardized manufacturing system for cell and gene therapies that enhances biological performance while minimizing batch failures and reducing costs. This technology addresses the challenges of high manufacturing costs and low throughput, enabling scalable production and wider patient access to lifesaving treatments.

Kytopen develops a non-viral gene delivery platform, Flowfect®, that utilizes continuous fluid flow and electric fields to efficiently deliver mRNA, DNA, and CRISPR Cas9 RNP to billions of cells in minutes. This technology addresses the challenges of cell therapy manufacturing by enabling scalable and customizable transfection processes from discovery to large-scale production.

Turbine's Simulated Cell™ platform utilizes AI to predict biological responses by simulating experiments across various models, including engineered cell lines and patient samples. This technology accelerates drug development by generating actionable insights in half the time of traditional methods, enabling researchers to identify optimal experimental pathways for novel cancer therapies.

Newcells Biotech specializes in developing induced pluripotent stem cell-derived in vitro models for drug discovery, focusing on human tissue simulations such as retinal, kidney, and lung models. Their services provide critical data on drug efficacy and safety, enhancing the predictive accuracy of pre-clinical studies and facilitating clinical translation.

The startup develops a machine platform that integrates silicon chip technology with microfluidic processing for the large-scale manufacturing of personalized cell therapies. This technology enables real-time control and manipulation of cellular processes, providing cost-effective and safe treatments tailored for individual cancer patients.

Doppl supplies industry‑standard organoid models for disease modeling and personalized medicine, offering custom model development, toxicity screening, and epithelial fluid transport assays. Their portfolio supports preclinical drug development across oncology, inflammatory, rare, and immuno‑oncology applications. The company also provides a crowd‑sourced bio‑base of donor samples to enable scalable, high‑quality organoid research.

Ixaka is a private cell and gene therapy company that utilizes the body's natural mechanisms to develop targeted treatments for various diseases. By harnessing advanced cellular technologies, Ixaka aims to improve patient outcomes and reduce the reliance on traditional pharmaceutical interventions.

Genewity B.V. develops autologous thymus tissue using gene-modified induced pluripotent stem cells to restore immune function in patients with congenital athymia and autoimmune disorders. This technology addresses the lack of effective treatments for severe immune deficiencies by creating patient-specific thymic organoids that enhance T-cell development and immune tolerance.

2seventy bio develops immuno-oncology cell therapies that utilize engineered T cells to target and eliminate cancer cells. The company aims to extend patients' lives by providing effective treatment options that address the limitations of current cancer therapies.

TC BioPharm develops an allogeneic gamma delta T cell therapy platform that provides scalable, "off the shelf" CAR-T treatments for hematological and solid tumors. This technology reduces side effects and off-tumor toxicity, enabling broader patient access and more efficient manufacturing processes.

This bio-therapeutics company develops and enhances cell-based therapies targeting cancer and chronic diseases through advanced cellular engineering techniques. Their approach aims to improve treatment efficacy and patient outcomes by optimizing the functionality and delivery of therapeutic cells.

Enduro Genetics provides Enduro Sense, a genetic plugin that enhances the performance of production strains by linking high product yield to cell growth, thereby maintaining a stable population of high-producing variants during fermentation. This technology addresses the issue of declining production efficiency in large-scale bioproduction by ensuring consistent high yields and titer across various organisms and processes.

Streamline Bio provides an autonomous, AI-driven precision robotic platform for end-to-end cell and gene therapy (CGT) production. This plug-and-play technology integrates seamlessly into existing biomanufacturing infrastructure without requiring facility redesigns or custom enclosures. The platform delivers repeatable precision, reduces manual touchpoints, and scales flexibly across autologous and allogeneic workflows.

The startup has developed a second-life battery cell platform that employs patented technology to measure, select, and balance both new and used battery cells at an industrial scale. This platform provides industrial customers with a sustainable and cost-effective solution for their battery requirements, addressing the need for reliable and long-lasting battery products.

faCellitate develops polymeric coatings that modify labware surfaces to create inert, cell-repellent environments for advanced cell culture. Their BIOFLOAT™ technology enables the reproducible formation of consistent spheroids and organoids for 3D cell culture applications. The company also offers BIOINSTRUCT™ coatings optimized for defined, xeno-free stem cell expansion.

Sensible Bio operates a cell-based mRNA design and manufacturing platform to produce pure mRNA therapeutics. This approach overcomes limitations of synthetic mRNA by yielding products with low immunogenicity. The platform enables a new paradigm for design-based biology in therapeutic development.

Qkine develops and manufactures high-quality, animal-free growth factor proteins specifically for stem cell, organoid, and cellular agriculture applications, ensuring consistent bioactivity through rigorous quality control. Their products address the need for reproducible and reliable biological materials in research and industry, enhancing scientific outcomes across various fields.

ViroCell Biologics is a Contract Development and Manufacturing Organization (CDMO) specializing in the design, optimization, and GMP manufacturing of lentiviral and retroviral vectors. The company focuses on de-risking early-stage development by engineering complex viral vectors with specific performance and safety attributes. This expertise enables the acceleration of novel cell and gene therapies toward clinical trial readiness.

A4CELL develops SPAchip suspended planar-array chips for real-time monitoring of individual living cells, providing researchers with precise data on cellular behavior. This technology enhances the understanding of cell biology and supports advancements in personalized medicine by enabling detailed analysis of live cell dynamics.

This company develops organ-on-chip devices and assays for drug discovery and diagnostics. They provide products like chip devices for invasion and chemotaxis, alongside CRO services for assessing cell-cell interactions in 3D cell culture using their chip, enhanced by AI-based image analysis for quantitative assessment.

CryoLogyx develops cryopreserved, assay-ready cells that are directly adhered to microplates, enabling experiments to commence just 24 hours post-thaw. This technology enhances the precision and efficiency of cell-based research, significantly reducing the time and resources required for routine cell culture.

HemostOD engineers and manufactures universal platelets from a stable megakaryocytic cell line using advanced microfluidic technologies, providing a scalable and rapid source of high-quality platelets. This technology addresses the need for effective treatments in patients with thrombocytopenia and facilitates targeted delivery of therapeutic agents in regenerative medicine applications.

Genenet Technology develops proprietary gene circuit designs by integrating deep learning algorithms to mimic artificial neural networks. This novel biocomputing method enables advanced control over gene expression for applications in synthetic biology and bioproduction. The company provides genetic circuit design services, R&D consultation, and technology licensing for drug discovery, cell and gene therapy, and organoid-on-chip research.

Cellular Origins provides the Constellation ecosystem, an advanced mobile robotic platform designed for cell therapy manufacturing automation. This system integrates existing processes and technologies to deliver GMP-compliant, full automation for scaling production. The platform increases efficiency, optimizes facility space, and reduces the cost of goods for cell and gene therapy developers.